Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $46.67 +0.43 (+0.93%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Revolution Medicines Stock (NASDAQ:RVMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$45.18▼$47.0050-Day Range$34.70▼$46.2452-Week Range$29.17▼$62.40Volume2.25 million shsAverage Volume1.89 million shsMarket Capitalization$8.72 billionP/E RatioN/ADividend YieldN/APrice Target$73.67Consensus RatingBuy Company Overview Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance. The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations. These candidates are being evaluated in various phases of clinical development across solid tumors, with the goal of delivering first-in-class or best-in-class therapies for patients with limited treatment options. Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines operates research facilities in North America and collaborates with academic institutions and industry partners to accelerate innovation. The management team comprises experienced executives with deep expertise in oncology drug discovery, guiding the company’s strategic partnerships and clinical advancement efforts.AI Generated. May Contain Errors. Read More Revolution Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreRVMD MarketRank™: Revolution Medicines scored higher than 85% of companies evaluated by MarketBeat, and ranked 150th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingRevolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Upside PotentialRevolution Medicines has a consensus price target of $73.67, representing about 59.4% upside from its current price of $46.21.Amount of Analyst CoverageRevolution Medicines has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Revolution Medicines are expected to decrease in the coming year, from ($3.49) to ($3.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.63% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Revolution Medicines has recently increased by 8.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.81 Percentage of Shares Shorted9.63% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Revolution Medicines has recently increased by 8.89%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.00 News SentimentRevolution Medicines has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Revolution Medicines this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows4 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $400,986.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Stock News HeadlinesJack Anders Sells 4,762 Shares of Revolution Medicines (NASDAQ:RVMD) StockSeptember 5, 2025 | insidertrades.comRevolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial ResultsSeptember 12 at 4:32 AM | finance.yahoo.comTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the biggest money moves of the last 30 years – including the internet, the tech boom, and bitcoin (before it soared 8,000%). Today, he's a multimillionaire tech investor. And he says Congress just passed a radical new law that could create more millionaires in the years ahead than anything else.September 12 at 2:00 AM | Stansberry Research (Ad)Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Wedbush Analyst SaysSeptember 12 at 3:53 AM | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives $72.00 Consensus Target Price from BrokeragesSeptember 12 at 2:21 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up After Analyst UpgradeSeptember 12 at 2:43 AM | americanbankingnews.comRevolution Medicines announces results from daraxonrasib Phase 1 trialsSeptember 11 at 10:54 AM | msn.comRevolution Medicines, Inc. (RVMD) Discussion On Metastatic Pancreatic Cancer Update Call (Transcript)September 11 at 9:05 AM | seekingalpha.comSee More Headlines RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $43.74 on January 1st, 2025. Since then, RVMD shares have increased by 5.6% and is now trading at $46.2110. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by $0.37. The firm's revenue for the quarter was up .0% on a year-over-year basis. Read the conference call transcript. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include State Street Corp (2.52%), Bellevue Group AG (2.45%), Holocene Advisors LP (1.94%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today9/12/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVMD CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Price Target for Revolution Medicines$73.21 High Price Target$99.00 Low Price Target$60.00 Potential Upside/Downside+58.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$600.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.78% Return on Assets-35.63% Debt Debt-to-Equity Ratio0.13 Current Ratio11.79 Quick Ratio11.79 Sales & Book Value Annual Sales$11.58 million Price / Sales746.43 Cash FlowN/A Price / Cash FlowN/A Book Value$13.47 per share Price / Book3.43Miscellaneous Outstanding Shares186,930,000Free Float171,604,000Market Cap$8.64 billion OptionableOptionable Beta1.12 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RVMD) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.